QUIMATRYX is a biotechnology startup founded in 2015 with a dedicated focus on the discovery and development of innovative drugs targeting epigenetic aspects of cancer. The company has developed a high-performing HDAC6 selective inhibitor, QTX125, aimed at reducing treatment side effects and enhancing therapeutic activity compared to other HDAC inhibitors. Their advanced compounds have demonstrated superior in vivo efficacy and safety profiles for treating pancreatic cancer and other invasive tumors. With a mission to address unmet medical needs in cancer treatment, QUIMATRYX is positioned as a promising player in the biopharmaceutical landscape.
There is no investment information
No recent news or press coverage available for QUIMATRYX.
We care about your data, and we'd love to use cookies make your experience better.
